Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug

Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration had rejected accelerated approval of its experimental Alzheimer's drug because it had not submitted enough trial data from patients who were treated for at least a year.